Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15950985 | 0.82 | MEN1 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL15950984 | 0.82 | MEN1 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL15940792 | 0.82 | MEN1 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL904415 | 0.82 | ALDH1A1 (0.47) | KMT2AGRIN2B | |
| SCHEMBL11002249 | 0.82 | MEN1 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL904815 | 0.81 | PSEN1 (0.37) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL29132155 | 0.80 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL904636 | 0.79 | PRSS1 (0.55) | NPC1RAB9AMEN1KMT2ABCHE | |
| SCHEMBL15198664 | 0.79 | PRSS1 (0.48) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL904450 | 0.78 | GAA (0.46) | SMN1; SMN2NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621899-B1 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2015-10-21 | — | — | EP | disclosed |
| US-8822463-B2 | Methylcyclohexane derivatives and uses thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-09-02 | — | — | US | disclosed |
| US-8822463-B2 | Methylcyclohexane derivatives and uses thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-09-02 | — | — | US | disclosed |
| US-8822463-B2 | Methylcyclohexane derivatives and uses thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-09-02 | — | — | US | disclosed |
| US-20130217686-A1 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-08-22 | — | — | US | disclosed |
| US-20130217686-A1 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-08-22 | — | — | US | disclosed |
| US-20130217686-A1 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-08-22 | — | — | US | disclosed |
| EP-2621899-A2 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012044046-A2 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217686-A1 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | OPRK1, OPRM1, OPRL1 | SMN1; SMN2 325/4885NPC1 1549/4885RAB9A 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.